Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Skin Prick Solution for Blattella Germanica (Wolwo Bio-Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Skin Prick Solution for Blattella Germanica (Wolwo Bio-Pharmaceutical): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals.
Latest Hotspot
8 min read
Progressive Pulmonary Fibrosis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Progressive Pulmonary Fibrosis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development…
8 min read
RPS6KA1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for RPS6KA1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Skin Prick Solution for Cat Fur (Wolwo Bio-Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Skin Prick Solution for Cat Fur (Wolwo Bio-Pharmaceutical): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Idiopathic Pulmonary Fibrosis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Idiopathic Pulmonary Fibrosis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Skin Prick Solution for Platanus Acerifolia Pollen (Wolwo Bio-Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Skin Prick Solution for Platanus Acerifolia Pollen (Wolwo Bio-Pharmaceutical): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP.
Latest Hotspot
8 min read
COPD Disease Modification Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 COPD Disease Modification clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white...
Latest Hotspot
8 min read
Citrulline Malate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Citrulline Malate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ROR2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for ROR2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Severe Eosinophilic Asthma Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Severe Eosinophilic Asthma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white...
Latest Hotspot
8 min read
Tetravalent vaccine (ApicHope Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Tetravalent dengue virus vaccine(Instituto Butantan): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Factor VIII (Bohui Bio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Factor VIII (Bohui Bio): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.